Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
7.58 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Olema Pharmaceuticals, Inc. |
| Symbool | OLMA |
| Munteenheid | USD |
| Prijs | 7.58 |
| Beurswaarde | 520,247,994 |
| Dividendpercentage | 0% |
| 52-weken bereik | 2.86 - 13.93 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Sean P. Bohen M.D., Ph.D. |
| Website | https://www.olema.com |
An error occurred while fetching data.
Over Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)




